Issue 2, 2012

The differential effect of apoferritin-PbS nanocomposites on cell cycle progression in normal and cancerous cells

Abstract

We report the effects induced by near-infrared apoferritin-PbS (AFt-PbS) nanocomposites on cell cycle progression in non-tumorigenic and cancerous human cells. By using flow cytometry and Annexin V assay, we show that the cell cycle of non-tumorigenic cells is not altered by exposure to AFt-PbS nanoparticles at concentrations up to 1 mg mL−1. In contrast, exposure of human-derived breast cancer cell lines to AFt-PbS at concentrations > 0.2 mg mL−1 triggers apoptotic cell death. The selective death of cancerous cells and the near-infrared fluorescence properties of AFt-PbS could be exploited in both nanomedicine and in vivo imaging studies.

Graphical abstract: The differential effect of apoferritin-PbS nanocomposites on cell cycle progression in normal and cancerous cells

Supplementary files

Article information

Article type
Paper
Submitted
26 Jul 2011
Accepted
19 Oct 2011
First published
07 Nov 2011

J. Mater. Chem., 2012,22, 660-665

The differential effect of apoferritin-PbS nanocomposites on cell cycle progression in normal and cancerous cells

L. Turyanska, T. D. Bradshaw, M. Li, P. Bardelang, W. C. Drewe, M. W. Fay, S. Mann, A. Patanè and N. R. Thomas, J. Mater. Chem., 2012, 22, 660 DOI: 10.1039/C1JM13563E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements